CliffBio
biologic

Omnitrope

somatropin

Loss of exclusivityJanuary 2020projected — 12-year biologic exclusivity estimate
CompanySandoz →See this company's full patent-cliff portfolio

Drug detail

Brand nameOmnitrope
Active ingredientsomatropin
Strength5MG/1.5ML
Dosage formInjection
RouteSubcutaneous
ModalityBiologic
FDA approvalJanuary 2008
Marketing statusRx

More from Sandoz

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

Omnitrope patent cliff — loss of exclusivity January 2020 | CliffBio